Abstract

The aim of this study was to study the serotypes and clonal diversity of pneumococci causing invasive pneumococcal disease in Catalonia, Spain, in the era of 13-valent pneumococcal conjugate vaccine (PCV13). In our region, this vaccine is only available in the private market and it is estimated a PCV13 vaccine coverage around 55% in children. A total of 1551 pneumococcal invasive isolates received between 2010 and 2013 in the Molecular Microbiology Department at Hospital Sant Joan de Déu, Barcelona, were included. Fifty-two serotypes and 249 clonal types—defined by MLST—were identified. The most common serotypes were serotype 1 (n = 182; 11.7%), 3 (n = 145; 9.3%), 19A (n = 137; 8.8%) and 7F (n = 122; 7.9%). Serotype 14 was the third most frequent serotype in children < 2 years (15 of 159 isolates). PCV7 serotypes maintained their proportion along the period of study, 16.6% in 2010 to 13.4% in 2013, whereas there was a significant proportional decrease in PCV13 serotypes, 65.3% in 2010 to 48.9% in 2013 (p < 0.01). This decrease was mainly attributable to serotypes 19A and 7F. Serotype 12F achieved the third position in 2013 (n = 22, 6.4%). Despite their decrease, PCV13 serotypes continue to be a major cause of disease in Spain. These results emphasize the need for complete PCV13 vaccination.
**Introduction**

*Streptococcus pneumoniae* is a major cause of morbidity and mortality worldwide, especially among young children and the elderly. This pathogen colonizes the nasopharynx as part of the normal flora in children [1] and is the leading bacterial cause of pneumonia, sepsis and meningitis [2]. During asymptomatic nasopharyngeal colonization stages, *S. pneumoniae* interplays with the host immune system through multiple and complex interactions. Imbalance due to host factors and microbiological factors are related with the propensity to cause serious invasive disease [3]. The capsule of pneumococcus is its main virulence factor. There are over 97 known serotypes but not all of them have the same capacity to cause invasive pneumococcal disease (IPD) [4].

Despite the high effectiveness reported for PCV7 worldwide [5–8], the lower vaccine serotype coverage found in some countries compared to the USA [9] made necessary the development of two new conjugate vaccines, PCV10 and PCV13, which included a larger number of serotypes. PCV13 vaccine includes serotypes 1, 3, and 5 that were common in Europe, Asia, and Africa, and also serotype 6A, 7F and 19A. The majority of these serotypes had emerged after the implementation of PCV7 in our region [10].

Of note, although the Vaccination Advisory Committee of the Spanish Association of Pediatrics has recommended the routine administration of conjugate pneumococcal vaccines (PCV7 since 2001–2010 and currently PCV13) these vaccines have not been financed by the Catalan Public Health System and they have been only available in the private market. In our reference area, we estimated a PCV7 vaccination coverage of 47% in 2007 [10] and a PCV13 vaccine coverage of 55% in 2013 [11].

Although differences in the capsular type are the major determinant of the invasive disease potential of a strain, several studies have suggested that differences in both the invasive disease potential and the ability to cause disease are also influenced by the genetic background [12–14].

The aim of this study was to determine the pneumococcal serotypes and clonal types causing IPD in Catalonia, Spain, in the era of PCV13.

**Materials and Methods**

This research was approved by the Ethics and Clinical Research Committee from Hospital Sant Joan de Déu. No consent was asked to participants because the data were analyzed anonymously.

This was a prospective study which included all pneumococcal invasive isolates, adults and children, received between 2010 and 2013 from 26 health centers in Catalonia that were characterized by the Molecular Microbiology Department at University Hospital Sant Joan de Déu in Barcelona, Spain. In 2009, this laboratory was designated by the government of Catalonia, Spain, for molecular surveillance of invasive pneumococcal disease. In Catalonia, with a population of around 7 million and 1.4 million persons aged 18 years or younger, these 26 health centres captured 40.1% of all hospital admissions during 2012 [15].

On December 9, 2009, the European Medicine Agency (EMA) authorized the commercialization of Pneumococcal Conjugate Vaccine 13 (PCV13) in Europe [16]. Although in Catalonia the pneumococcal conjugate vaccine has not yet been incorporated into the official vaccination calendar, PCV13 was included in the schedule recommended by the Spanish Association of Paediatrics in 2010 [17]. In fact, many paediatricians recommend this vaccine in their private practices, and vaccination coverage was estimated at 55.1% for PCV13, 12.5% for PCV7 and 1.4% for PCV10 vaccine in 2013 [11].
IPD was defined as the presence of clinical findings of infection together with isolation by culture of *S. pneumoniae* in sterile fluid samples (blood, cerebrospinal fluid or any other sterile fluid).

Microbiological identification and antimicrobial susceptibility

All pneumococcal invasive isolates were cultured on blood agar plates (Columbia agar supplemented with 5% sheep blood; bioMérieux) and were identified in the different health centers by standard microbiological methods including optochin sensitivity test and an antigenic test. The minimum inhibitory concentrations (MIC) to antibiotics were determined with the agar dilution technique. Antibiotic susceptibilities were defined according to the breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [18]. Multidrug resistance was defined as non-susceptibility to three or more antimicrobial agents [19].

**Serotype analysis.** The identification of capsular pneumococcal serotypes was performed at our laboratory using multiplex PCR combined with fragment analysis and automated fluorescent capillary electrophoresis. This technique implemented in our Molecular Microbiology Department in 2010 and allows the detection of 40 serotypes/serogroups: (1, 2, 3, 4, 5, 6A/6B, 6C, 7F/7A, 7C/(7B/40), 8, 9V/9A, 9N/9L, 10A, 10F/(10C/33C), 11A/11D/11F, 12F/(12A/44/46), 13, 14, 15A/15F, 15B/15C, 16F, 17F, 18/(18A/18B/18C/18F), 19A, 19F, 20, 21, 22F/22A, 23A, 23B, 23F, 24/(24A/24B/24F), 31, 33F/(33A/37), 34, 35A/(35C/42), 35B, 35F/47F, 38/25F, and 39) [20]. Pneumococcal strains were also sent to the National Center for Microbiology of Majadahonda (Madrid, Spain) to complete the serotype detection with Quellung reaction [21] and the antimicrobial susceptibility study.

**Clonal analysis.** Clonal analysis was performed with multilocus sequence typing (MSLT). MLST was performed as reported elsewhere [22]. The assignment of alleles and sequence types (ST) was carried out using the software at the pneumococcal web page http://pubmlst.org/spneumoniae/. Analysis of ST and assignment to clonal complex were performed with the eBURST program [23]. STs that shared six of seven allelic (single locus [SLV]) variants were considered a clonal complex.

Statistical analysis

We used the $X^2$ test or Fisher’s exact test to compare proportions. Statistical analyses were performed using SPSS for Windows, version 17.0 (SPSS). We calculated 95% CIs, and 2-sided $P$ values < .05 were considered to be statistically significant.

Genetic diversity of isolate populations was estimated using Simpson’s numerical index of discrimination (SID), using the website: www.comparingpartitions.info. To compare the SID values from the different groups of data the $p$ value was calculated using the online tool available in the same web page.

Results

During the study period a total of 1576 pneumococcal invasive isolates were received, of which 25 were not viable for clonal analysis and serotyping. A total of 1551 strains (98.4%) were included in the study; serotype identification was performed in all of them. Among the 1551 isolates, 910 (58.7%) were from males and 641 (41.3%) from females, with a mean age of 50.7 years. 159 (10.2%) isolates were from children less than 2 years old, 143 (9.2%) from the age group between 2 to less than 5 years, 76 (4.9%) from the age 5 to less than 18 years, 561 (36.1%) from the age 18–65 and 612 (39.4%) in patients older than 65 years old.
All 1551 isolates of IPD had positive cultures: blood (1400), pleural fluid (78), cerebral spinal fluid (58), peritoneal fluid (2), joint fluid (5), ascites liquid (5) and pericardial fluid (1). In two of the positive cultures the sample type was not reported.

The most important clinical manifestation in the study period was pneumonia ($n$ = 1078, 69.5%), including the diagnostics of non-complicated pneumonia ($n$ = 980, 63.2%) and complicated pneumonia ($n$ = 98, 6.3%), followed by bacteremia/sepsis ($n$ = 315, 20.3%) and meningitis ($n$ = 127, 8.2%). During the study period, although pneumonia stayed as the main clinical manifestation, a change in the proportion of the other diagnoses was observed. The proportion of meningitis and complicated pneumonia decreased from 44 cases (10.3%) and 29 cases (6.8%) in 2010 to 21 cases (6.1%) and 14 cases (4.1%) in 2013, with $p = 0.116$ and $p = 0.110$, respectively. On the other hand, there was a significant increase in the proportion of cases with bacteremia/sepsis from 68 cases (15.9%) in 2010 to 86 cases (25.1%) in 2013, $p = 0.010$.

According to age group, pneumonia was the main clinical manifestation diagnosed in all ages except in the group of children less than 2 years old where it was overcome by bacteremia/sepsis.

During the study period most of the $S. pneumoniae$ invasive isolates were susceptible to the majority of the antibiotics analyzed. Penicillin (meningeal breakpoints), erythromycin and tetracycline presented a similar proportion of resistant isolates during the study period: 23.6%, 19.2% and 22.2%, respectively. Chloramphenicol, cefotaxime and levofloxacin showed lower proportions of resistance: 7%, 3% and 1%, respectively. However, three serotype 19A isolates (clonal type ST320) showed a MIC to cefotaxime $\geq$4 μg/ml. These strains were isolated in one child and two adults with pneumonia. No isolates were resistant to vancomycin. Overall, the proportion of multiresistance presented in the study was 13.2%. No significant differences in the rate of MDR were observed when comparing PCV13 serotypes vs non-PCV13 serotypes. Children less than 2 years old showed significantly higher proportion of MDR compared to older patients: 49 of 159 (30.8%) vs 156 of 1392 (11.2%) ($p<0.01$).

### Serotype distribution of invasive isolates

Overall, 52 different serotypes were found. The most common serotypes found were serotype 1 ($n$ = 182, 11.7%), serotype 3 ($n$ = 145, 9.3%), serotype 19A ($n$ = 137, 8.8%) and serotype 7F ($n$ = 122, 7.9%) (Fig 1). In total, 14.9% were serotypes included in PCV7, 55.6% were serotypes included in PCV13 and 44.4% were non-vaccine serotypes.

According to age group, in children less than 2 years old the main serotypes were serotype 19A ($n$ = 32, 20.1%), serotype 24F ($n$ = 17, 10.7%) and serotype 14 ($n$ = 15, 9.4%). In the age group between 2 and 5 years old, the most common serotype was serotype 1 ($n$ = 48, 33.6%), as well as in the age group between 5 years old and 18 ($n$ = 45, 59.2%). In the group between 18 years old and 65, the main serotypes were 7F ($n$ = 62, 11.05%), 1 ($n$ = 61, 10.9%) and 12F ($n$ = 52, 9.3%). And in the age group older than 65 the main serotypes were serotypes 3 ($n$ = 77, 12.6%), 19A ($n$ = 60, 9.8%) and 14 ($n$ = 45, 7.3%).

According to year, in 2010 the most common serotypes were serotype 19A ($n$ = 52, 12.2%), serotype 7F ($n$ = 46, 10.8%) and serotype 1 ($n$ = 45, 10.5%). In 2011, the main serotypes found were serotypes 1 ($n$ = 42, 10.2%), 3 ($n$ = 41, 10%) and 19A ($n$ = 39, 9.5%). In 2012, the most common serotypes were serotype 1 ($n$ = 53, 14.3%), 12F ($n$ = 34, 9.2%) and 3 ($n$ = 29, 7.8%). And in 2013, they were serotypes 1 ($n$ = 42, 12.2%), 3 ($n$ = 34, 9.9%), 12F ($n$ = 22, 6.4%) and 14 ($n$ = 22, 6.4%).

During the study period there was an evolution in the serotypes included in the different conjugate vaccines. The serotypes included in the PCV7 maintained their proportion along the period of study, 16.6% in 2010 to 13.4% in 2013, whereas there was a significant proportional decrease in PCV13 serotypes from 65.3% in 2010 to 48.9% in 2013 ($p<0.01$). Consequently,
non-PCV13 serotypes showed a proportional significant increase, from 34.7% in 2010 to 51% in 2013 ($p<0.01$) (Table 1).

### Clonal diversity of serotypes

Overall, we identified 249 ST in the study, 45 of which were new (ST5223, ST5224, ST5686, ST5687, ST5688, ST5823, ST5824, ST5825, ST5826, ST5829, ST6004, ST6005, ST6006, ST6166, ST6394, ST6395, ST6518, ST6519, ST6520, ST6521, ST6999, ST7000, ST7001, ST7002, ST7314, ST7855, ST8077, ST8492, ST9038, ST9039, ST9040, ST9041, ST9419, ST9420, ST9421, ST9439, ST9440, ST9441, ST9737, ST9738, ST9742, ST9755, ST9756, ST9758, ST9942). Eight of these new STs also presented one new allele (ST8492, ST9439, ST9440, ST9441, ST9755, ST9756, ST9758, ST9942). The most frequent clonal types found in the study were ST306 ($n = 154, 9.9\%$), ST191 ($n = 111, 7.2\%$), ST989 ($n = 85, 5.5\%$) and

### Table 1. Serotype distribution according to age group and year.

| Age group       | PCV7(%) | PCV10(%) | PCV13(%) | Non PCV13(%) |
|-----------------|---------|----------|----------|--------------|
| <2 años         | 34 (21.4) | 50 (31.4) | 94 (59.1) | 65 (40.9)    |
| 2 to <5 años    | 20 (14.0) | 82 (57.3) | 102 (71.3) | 41 (28.7)    |
| 5 to <18 años   | 4 (5.3)   | 56 (73.7) | 61 (80.3) | 15 (19.7)    |
| 18 to 65 años   | 81 (14.4) | 210 (37.4) | 297 (52.9) | 264 (47.1)   |
| >65 años        | 92 (15.0) | 163 (26.6) | 309 (50.5) | 303 (49.5)   |
| Año             |         |          |          |              |
| 2010            | 71 (16.6) | 182 (42.6) | 279 (65.3) | 148 (34.7)   |
| 2011            | 60 (14.6) | 144 (35.1) | 231 (56.3) | 179 (43.7)   |
| 2012            | 54 (14.6) | 128 (34.5) | 185 (49.9) | 186 (50.1)   |
| 2013            | 46 (13.4) | 107 (31.2) | 168 (48.9) | 175 (51.0)   |

doi:10.1371/journal.pone.0151125.t001

![Fig 1. Frequency of serotypes causing invasive pneumococcal disease during the years 2010, 2011, 2012 and 2013.](doi:10.1371/journal.pone.0151125.g001)
ST180 (n = 80, 5.2%). A population snapshot of the 1551 isolates based on an eBURST analysis was represented in Fig 2. The major clonal complexes found were CC306, CC191, CC156, CC180, CC230, CC433, CC53 and CC320. Thirty-three STs expressed serotypes that were not present in the MLST database showing potential capsular switching (ST53, ST63, ST109, ST193, ST205, ST280, ST306, ST310, ST338, ST405, ST605, ST646, ST871, ST989, ST1046, ST1143, ST1167, ST1201, ST1816, ST2013, ST2217, ST2372, ST2557, ST2670, ST3133, ST4310, ST4475, ST4828, ST5033, ST5224, ST5688, ST6532 and ST8300).

Table 2 shows the different ST expressed by the different serotypes found in our collection, and the clonal diversity of each serotype was determined using the Simpson’s Index of Diversity (SID).

**Discussion**

The results obtained in this study allowed us to observe the evolution experienced by serotypes after the introduction of PCV13 in our geographical area. After the introduction of the vaccine and, similarly to other countries with higher vaccine coverage, there has been a significant proportional decrease in the PCV13 serotypes and, as a consequence, a proportional increase of non-PCV13 serotypes [24–28]. However, PCV13 serotypes continue to be responsible for a high burden of the disease, probably due to the low vaccine coverage which is estimated in only 40% of target population in our geographical area [13]. Despite this limited coverage, serotypes 19A and 7F experienced an important decrease during the study period; a similar decrease was not observed for serotypes 1, 3 and 14. In the non-vaccine serotypes group, it is worth mentioning the increase observed for serotype 12F along the study period, and compared with previous data obtained before the introduction of PCV13 in our region [29]. This increase was also
Table 2. Clonal diversity of serotypes causing IPD.

| Serotype | SID* | CI (95%) | n* |
|----------|------|----------|----|
| 1        | 0.283 | 0.200–0.367 | 182 |
| 3        | 0.635 | 0.569–0.701   | 145 |
| 19A       | 0.830 | 0.788–0.872   | 137 |
| 7F        | 0.201 | 0.104–0.298   | 122 |
| 14        | 0.586 | 0.472–0.700   | 102 |
| 12F       | 0.272 | 0.160–0.384   |    |
| 8         | 0.631 | 0.525–0.736   | 77  |
| 22F       | 0.251 | 0.111–0.391   | 67  |
| 24F       | 0.690 | 0.612–0.769   | 65  |
| 6C        | 0.779 | 0.667–0.892   | 41  |
| 9N        | 0.772 | 0.662–0.881   | 37  |
| 10A       | 0.123 | 1.000–0.278   | 32  |
| 4         | 0.825 | 0.693–0.957   | 29  |
| 11A       | 0.571 | 0.401–0.741   | 29  |
| 16F       | 0.817 | 0.729–0.906   | 28  |
| 5         | 0.510 | 0.382–0.638   | 27  |
| 23A       | 0.587 | 0.369–0.804   | 25  |
| 23B       | 0.157 | 1.000–0.348   | 25  |
| 9V        | 0.740 | 0.649–0.831   | 25  |
| 6B        | 0.793 | 0.629–0.958   | 24  |
| 15A       | 0.640 | 0.410–0.870   | 23  |
| 19F       | 0.943 | 0.896–0.990   | 21  |
| 15B       | 0.912 | 0.851–0.974   | 19  |
| 6A        | 0.901 | 0.794–1.000   | 19  |
| 31        | 0.419 | 0.140–0.698   | 17  |
| 23F       | 0.765 | 0.631–0.898   | 17  |
| 33F       | 0.758 | 0.617–0.900   | 16  |
| 38        | 0.385 | 0.082–0.678   | 14  |
| 18C       | 0.718 | 0.570–0.866   | 13  |
| 15C       | 0.844 | 0.743–0.946   | 10  |
| 17F       | 0.417 | 0.047–0.786   | 9   |
| 35B       | 0.750 | 0.579–0.921   | 9   |
| 35F       | 0.933 | 0.805–1.000   | 6   |
| 34        | 0.000 | 0.000–0.000   | 5   |
| 20        | 0.700 | 0.349–1.000   | 5   |
| 29        | 0.833 | 0.583–1.000   | 4   |
| 11F       | 0.000 | 0.000–0.000   | 4   |
| 21        | 0.667 | 0.667–0.667   | 4   |
| 13        | 0.000 | 0.000–0.000   | 2   |
| 7A        | 0.000 | 0.000–0.000   | 2   |
| 9L        | 1.000 | 1.000–1.000   | 2   |
| 25        | 1.000 | 1.000–1.000   | 1   |
| 27        | 1.000 | 1.000–1.000   | 1   |
| 28        | 1.000 | 1.000–1.000   | 1   |
| 24B       | 1.000 | 1.000–1.000   | 1   |

(Continued)

Serotypes and Clonal Types after PCV13
noticed in the post PCV13 studies of Israel, Germany and Uruguay previously cited [24,26,28]. In our study, a low index of diversity of serotype 12F was observed, with high proportion of ST989, a clonal type previously detected in children with meningitis in Gambia [30]. Also interesting, serotype 24F was the second most common serotype in children less than 2 years old during the study period when analyzing the results by age groups. The major clone detected in serotype 24F was ST230, a multidrug resistant clone related with the increase of serotype 19A in Bulgaria, Portugal and in our geographical area [29,31,32]. A previous study conducted in our area also observed an increase in the rate of serotype 24 several years after PCV7 introduction associated with the clonal expansion of this genotype [33].

The clonal analysis of serotype 19A revealed the important presence of the multiresistant clone ST320 in 46 of 137 (33.5%) serotype 19A isolates, but a high index of clonal diversity was found which reflects the high adaptation of this serotype. The association of serotype 19A with ST320 was previously described in our area as a contributor to the emergence of this serotype after the introduction of PCV7 [34]. The high proportion of ST320 among our isolates (three of them showing high resistance to cefotaxime) is worrisome as well as the still high presence of this serotype despite being included in PCV13, which highlights the need for complete vaccination to prevent disease caused by this serotype.

A worrying result is the proportionally high prevalence of serotype 14 found in our results. This serotype was included in PCV7, the first generation of conjugate vaccines available in Spain since 2001. While other PCV7 serotypes were almost non-existent in our study, serotype 14 continues to be one of the most prevalent in younger children and older people. Its clonal composition revealed that ST156 was detected in more than 65 of 102 (63%) serotype 14 isolates. A previous study performed by our group found that the pilus was present in all ST156 strains analyzed, while its general presence in the other clonal types was not frequent [35]. A study performed by Barocchi et al. showed in a murine model that a strain with pilus was more virulent than its non-piliated mutant [36]. Moreover, a study by Sjöström et al. suggested that the expression of pili in ST156 isolates contributed to the successful spread of this clone worldwide [37]. Although undoubtedly the low coverage of conjugate vaccines in our population could be facilitating its spread, we hypothesize that the high presence of this virulence factor in the serotype 14 isolates of our geographical area could be also related to the persistence of its circulation and their high invasiveness. Further studies are needed to know why serotype 14 continues to be so prevalent in our population.

Also noteworthy were the results about serotype 3. The present study confirms the results obtained for this serotype in previous publications of our group ranking as the second serotype

### Table 2. (Continued)

| Serotype | SID | CI (95%) | n° | CLONAL TYPES |
|----------|-----|----------|----|--------------|
| 11C      | 1.000 | 1.000–1.000 | 1  | 53           |
| 39       | 1.000 | 1.000–1.000 | 1  | 6040         |
| 18A      | 1.000 | 1.000–1.000 | 1  | 241          |
| 18B      | 1.000 | 1.000–1.000 | 1  | 113          |
| 18F      | 1.000 | 1.000–1.000 | 1  | 4863         |
| 22A      | 1.000 | 1.000–1.000 | 1  | 2557         |
| NT       | 2     |           |    |              |
| **Total**|       |           |    | **1551**     |

*SID, Simpson’s Index of Diversity. Years 2010, 2011, 2012 and 2013.*

doi:10.1371/journal.pone.0151125.t002
more frequently found causing IPD. In our previous studies serotype 3 was also found responsible of a high burden of disease in our area when detection and capsular typing was performed in direct sample by molecular techniques \cite{38–40}. These results differ from the ones previously obtained from Brueggemann et al. in England where serotype 3 was only found in carriage \cite{41}. Contradictory results have also been found with respect the clonal diversity of this serotype. Studies from Scotland and Singapore described a high clonal diversity for this serotype, while studies from Canada and The Netherlands found strong clonal homogeneity of serotype 3 in their countries \cite{42–45}. In our study a low index of diversity was found with CC180, which comprises ST180 and three SLV (ST3794, ST1380 and ST9420), being the major clonal type detected among serotype 3 isolates in our geographical area (82 of 145 isolates, 56.5%). In contrast, ST180 was associated with a small number of IPD cases in a pediatric study performed in the US during the 2008–2013 period \cite{46}.

Conclusion

In conclusion, despite the observed decrease of PCV13 serotypes, these serotypes continue to be the major serotypes causing invasive disease in our geographical area. These results emphasize the need for complete PCV13 vaccination in children to cover the main affected population and also to ensure the protection obtained by herd immunity. The study of the genetic population of the serotypes circulating in a geographical area might help to obtain useful information about temporal trends, geographical differences and changes in invasiveness.

Acknowledgments

We thank Dr. Asuncion Fenoll of the National Center of Microbiology for Quellung serotyping, Mª José Centelles-Serrano from Hospital Verge de la Cinta and Isabel Pujol from Hospital Sant Joan de Reus. We are also grateful for the availability of the public MLST database, which is located at the Imperial College of London.

Contributors

Members of the Catalan Study Group of Invasive Pneumococcal Disease are: S Hernandez and Conchita Izquierdo, General Directorate of Public Health of Government of Catalonia; A Gonzalez-Cuevas, Hospital Sant Joan de Déu de Sant Boi; R Bartolomé, Hospital del Vall d’Hebron; M Sierra, Hospital de Barcelona; N Peris, M Fernandez de Sevilla, I Jordan, M Triviño and JJ Garcia-Garcia, Hospital Sant Joan de Déu; M Motjé, Hospital Josep Trueta; M Morta, Althaia Xarxa Asistencial Manresa; A Gasos, Hospital de Martorell; E Sanfeliu, Hospital Sant Jaume d’Olot; F Ballester, Hospital Sant Joan de Reus; M Olsina, Hospital General de Catalunya; X Raga, Hospital Sant Pau i Santa Tecla; F Gómez-Bertomeu, Hospital Joan XXIII; MO Pérez- Moreno, Hospital Verge de la Cinta; and I Calvet, E Jou and C Sanjosé, Consorci Laboratori Intercomarcal.

Author Contributions

Conceived and designed the experiments: EdA CM-A. Analyzed the data: EdA CE CM-A. Contributed reagents/materials/analysis tools: SH-B CG MN GS AD PG CM NL. Wrote the paper: EdA CM-A. Reviewed the draft report: PC MJ RS-L. Reviewed the final version of the manuscript: EdA CM-A CE SH-B CG MN GS AD PG CM NL PC MJ RS-L.

References

1. Bogaert D, De Groot R, Hermans PW (2004) Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 4: 144–154. PMID: 14998500
2. World Health Organization (2007) Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Revue épidémiologique hebdomadaire/Section d'hygiène du Secrétariat de la Société des Nations. Weekly epidemiological record/Health Section of the Secretariat of the League of Nations. 82: 93–104.

3. Munoz-Almagro C, Bautista C, Arias MT, Boixeda R, Del Amo E, Borras C, et al. (2014) High prevalence of genetically-determined mannose binding lectin deficiency in young children with invasive pneumococcal disease. Clin Microbiol Infect. 20(10):0745–52. doi: 10.1111/1469-0691.12615 PMID: 24602163

4. Geno GL, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, et al. (2015) Pneumococcal capsules and their types: past, present and future. Clin Microbiol Rev. 28(3):871–99. doi: 10.1128/CMR.00024-15 PMID: 26085553

5. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. (2010) Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 201(1):32–41. doi: 10.1086/648595 PMID: 19947881

6. von Gottberg A, de Gouveja L, Tempia S, Quan V, von Mollendorf C, et al. (2014) Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med. 371(20):1889–1899. doi: 10.1056/NEJMc1401914 PMID: 22939907

7. Ben-Shimol S, Greenberg D, Givon-Lavi N, Elias N, Glikman D, Rubinstein U, et al. (2012) Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. Vaccine. 30(46):6600–6607. doi: 10.1016/j.vaccine.2012.08.012 PMID: 22939907

8. Miller E, Andrews N, Wright PA, Slack MP and George RC (2011) Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 11(10):760–768. doi: 10.1016/S1473-3099(11)70090-1 PMID: 21621468

9. Dinklecy EC, Yargic Z (2008) Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era. Expert Rev Vaccines. 7(9):1367–1394. doi: 10.1586/14760584.7.9.1367 PMID: 18980540

10. Muñoz-Almagro C, Jordan I, Gene A, Latorre C, García-García JJ, Pallares R (2008) Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 46(2):174–82. doi: 10.1086/524660 PMID: 18171247

11. Moraga-Llop F, García-García JJ, Díaz-Conradi A, Ciruela P, Martínez J, González S, et al. (2015) Vaccine failures in patients properly vaccinated with 13-valent pneumococcal conjugate vaccine in Catalonia, a region with low vaccination coverage. Pediatr Infect Dis J.

12. Browall S, Norman M, Tangrot J, Galanis I, Sjöström K, Dagerhamn J, et al. (2014) Intraclonal variations among Streptococcus pneumoniae isolates influence the likelihood of invasive disease in children. J Infect Dis. 209:377–388. doi: 10.1093/infdis/jiu481 PMID: 24009156

13. Sandgren A, Sjöström K, Olsson-Liljequist B, Christensson B, Samuelsson A, Kronvall G, et al. (2004) Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae. J Clin Microbiol. 42:451–9. PMID: 16421787

14. Sjöström K, Spindler C, Otqvist A, Kahlen H, Sandgren A, Köhler H-F, et al. (2006) Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis. 42:451–9. PMID: 16421787

15. Servei Català de la Salut. Informe del registre del conjunt mínim bàsic de dades (CMBD).

16. European public assessment report (EPAR). 2013. Prevenar 13: EPAR-Summary for the public. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001104/human_med_001220.jsp&mid=WC0b01ac058001d124.

17. Anon, Manual de vacunas en línea de la AEP. Comité Asesor de Vacunas. Available: http://vacunasaeap.org/documentos/manual/manual-de-vacunas. Accessed 2014 Jun 8.

18. European Committee on Antimicrobial Susceptibility Testing. 2013. Clinical breakpoints. Available: http://www.eucast.org/clinical_breakpoints/

19. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 18: 268–281. doi: 10.1111/j.1469-0691.2011.03570.x PMID: 21793988

20. Selva L, del Amo E, Brotos P, Munoz-Almagro C (2012) Rapid and easy identification of capsular serotypes of Streptococcus pneumoniae by use of fragment analysis by automated fluorescence-based capillary electrophoresis. J Clin Microbiol. 50: 3451–3457. doi: 10.1128/JCM.01368-12 PMID: 22875895
21. Austrian R (1976) The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med. 43: 699–709. PMID: 13297

22. Enright MC, Spratt BG (1998) A multilocus sequence typing scheme for *Streptococcus pneumoniae*: identification of clones associated with serious invasive disease. Microbiology. 144 (Pt 11):3049–60. PMID: 9846740

23. Feil EJ, Li BC, Aanensen DM, Hanage WP, Spratt BG (2004) eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol. 186: 1518–1530. PMID: 14973027

24. Regev-Yochay G, Paran Y, Bishara J, Oren I, Chowers M, Tzia B, et al. (2015) Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: A nationwide surveillance study. Vaccine. 33: 1135–1142. doi: 10.1016/j.vaccine.2015.01.030 PMID: 25373177

25. Lepoutre A, Varon E, Georges S, Dortéans F, Janoir C, Gutmann L, et al. (2015) Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012. Vaccine. 33: 359–366. doi: 10.1016/j.vaccine.2014.11.011 PMID: 25448105

26. Garcia Gabarró G, López Vega M, Pérez Giffoni G, Hernández S, Cardinal P, Félix V, et al. (2014) Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country. PLoS One. 9: e112337. doi: 10.1371/journal.pone.0112337 PMID: 25375647

27. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Moore RE, et al. (2015) Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 15: 301–309. doi: 10.1016/S1473-3099(14)71081-3 PMID: 25656600

28. van der Linden M, Falkenhorst G, Pennicario S, Imöhl M (2015) Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS One. 10(7): e0131494. doi: 10.1371/journal.pone.0131494 PMID: 26132078

29. Muñoz-Almagra C, Ciruela P, Esteva C, Marco F, Navarro M, Bartolome R, et al. (2011) Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain. J Infect. 63(2): 151–62. doi: 10.1016/j.jinf.2011.06.002 PMID: 21679725

30. Antonio M, Dada-Adegbola H, Biney E, Awine T, O’Callaghan J, Pfluger V, et al. (2008) Molecular epidemiology of pneumococci obtained from Gambian children aged 2–29 months with invasive pneumococcal disease during a trial of a 9-valent pneumococcal conjugate vaccine. BMC Infect Dis. 8: 81. doi: 10.1186/1471-2334-8-81 PMID: 18547404

31. Setchanova LP, Alexandrova A, Dacheva D, Mitov I, Kaneva R, Mitov V (2015) Dominance of multidrug-resistant Denmark(14)-32 (ST230) clone among *Streptococcus pneumoniae* serotype 19A isolates causing pneumococcal disease in Bulgaria from 1992 to 2013. Microb Drug Resist. 21(3):507–12. doi: 10.1093/mdr/213.010.0076 PMID: 25080213

32. Aguiar SI, Pinto FR, Nunes S, Serrano I, Melo-Cristino J, Sá-Leão R, et al. (2010) Denmark14-230 clone as an increasing cause of pneumococcal infection in Portugal within a background of diverse serotype 19A lineages. J Clin Microbiol. 48(1):101–8. doi: 10.1128/JCM.01069-09 PMID: 19964476

33. Ardanuy C, Tubau F, Pailares R, Calatayud L, Dominguez MA, Rojo D, et al. (2009) Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997–2007. Clin Infect Dis. 49(1):57–64. doi: 10.1086/594125 PMID: 19035779

34. Ardanuy C, Rojo D, Fenol L, Tarragó D, Calatayud L, Liñares J (2009) Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J Antimicrob Chemother. 64(3):507–510. doi: 10.1093/jac/dkp210 PMID: 19535383

35. Selva L, Ciruela P, Blanchette K, del Amo E, Pailares R, Orihuela CJ, et al. (2012) Prevalence and clonal distribution of pcpA, psrP and Pilus-1 among pediatric isolates of *Streptococcus pneumoniae*. PLoS One. 7: e41587. doi: 10.1371/journal.pone.0041587 PMID: 22848535

36. Barocchi MA, Ries J, Zogaj X, Hemsley C, Albiger B, Kanth A, et al. (2006) A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci U S A. 103: 2857–2862. PMID: 16481624

37. Sjöström K, Blomberg C, Fernebro J, Dagerhamn J, Morfeldt E, Barocchi MA, et al. (2007) Clonal success of pilated penicillin nonsusceptible pneumococci. Proc Natl Acad Sci U S A. 104: 12907–12912. PMID: 17644611

38. Del Amo E, Brotons P, Monsonis M, Triviño M, Itligo M, Selva L, et al. (2013) High invasiveness of pneumococcal serotypes included in the new generation of conjugate vaccines. Clin Microbiol Infect. 20(7):684–9. doi: 10.1111/1469-0691.12422 PMID: 24467648

39. Del Amo E, Selva L, de Sevilla MF, Ciruela P, Brotons P, Triviño M, et al. (2015) Estimation of the invasive disease potential of *Streptococcus pneumoniae* in children by the use of direct capsular typing in
40. Selva L, Ciruela P, Esteva C, de Sevilla MF, Codina G, Hernandez S, et al. (2012) Serotype 3 is a common serotype causing invasive pneumococcal disease in children less than 5 years old, as identified by real-time PCR. Eur J Clin Microbiol Infect Dis. 31(7):1487–95. doi: 10.1007/s10096-011-1468-7 PMID: 22052607

41. Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG (2003) Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis. 187: 1424–1432. PMID: 12717624

42. Jefferies JM, Smith A, Clarke SC, Dowson C, Mitchell TJ (2004) Genetic analysis of diverse disease-causing pneumococci indicates high levels of diversity within serotypes and capsule switching. J Clin Microbiol. 42: 5681–5688. PMID: 15583299

43. Jauneikaite E, Camon Jefferies JM, Vere Churton NW, Pin Lin RT, Hibberd ML, Clarke SC (2014) Genetic diversity of Streptococcus pneumoniae causing meningitis and sepsis in Singapore during the first year of PCV7 implementation. Emerg Microbes Infect. 3

44. Louie M, Louie L, Papia G, Talbot J, Lovgren, Simor AE (1999) Molecular analysis of the genetic variation among penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae serotypes in Canada. J Infect Dis. 179: 892–900. PMID: 10068584

45. Overweg K, Bogaert D, Sluijter M, Yother J, Dankert J, de Groot R, et al. (2000) Genetic relatedness within serotypes of penicillin-susceptible Streptococcus pneumoniae isolates. J Clin Microbiol. 38 (12):4548–4553. PMID: 11101594

46. Metcalf BJ, Gertz RE Jr, Gladstone RA, Walker H, Sherwood LK, Jackson D, et al. (2015) Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin Microbiol Infect. pii: S1198-743X(15)00813-7.